ID: ALA74138

Max Phase: Preclinical

Molecular Formula: C28H29F2NO4

Molecular Weight: 481.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C(OCCN2CCCC(C(=O)O)C2)(c2ccccc2)c2cccc(F)c2)cc1F

Standard InChI:  InChI=1S/C28H29F2NO4/c1-34-26-13-12-23(18-25(26)30)28(21-8-3-2-4-9-21,22-10-5-11-24(29)17-22)35-16-15-31-14-6-7-20(19-31)27(32)33/h2-5,8-13,17-18,20H,6-7,14-16,19H2,1H3,(H,32,33)

Standard InChI Key:  QPLCEYNIPVOVMI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 481.54

Molecular Weight (Monoisotopic): 481.2065

AlogP: 5.08

#Rotatable Bonds: 9

Polar Surface Area: 59.00

Molecular Species: ZWITTERION

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 2.98

CX Basic pKa: 8.92

CX LogP: 2.93

CX LogD: 2.92

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.43

Np Likeness Score: -0.97

References

1. Dhar TG, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL, Gluchowski C..  (1994)  Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.,  37  (15): [PMID:8057281] [10.1021/jm00041a012]

Source

Source(1):

• Scientific Literature